|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.420 EUR | -1.63% |
|
-12.00% | -3.97% |
| Jan. 14 | BRAIN Biotech AG Provides Revenue Guidance for the Year 2025/2026 | CI |
| Jan. 13 | BRAIN Biotech AG Reports Earnings Results for the Full Year Ended September 30, 2025 | CI |
| Fiscal Period: September | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -6.16 | -5.12 | -4.67 | -7.06 | -6.25 | |||||
Return on Total Capital | -9.99 | -8.12 | -7.77 | -15.3 | -15.45 | |||||
Return On Equity % | -13.77 | -16.67 | -28.34 | -60.16 | -150.49 | |||||
Return on Common Equity | -16.69 | -19.26 | -32.21 | -64.71 | -162.44 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 55.63 | 54.89 | 54.11 | 55.07 | 55.95 | |||||
SG&A Margin | 52.27 | 45.85 | 41.51 | 47.5 | 44.94 | |||||
EBITDA Margin % | -10.45 | -6.51 | -4.25 | -10.32 | -8.67 | |||||
EBITA Margin % | -14.53 | -9.68 | -7.04 | -13.63 | -12.74 | |||||
EBIT Margin % | -18.84 | -12.69 | -9.89 | -16.24 | -15.45 | |||||
Income From Continuing Operations Margin % | -11.93 | -12.61 | -14.43 | -20 | -23.56 | |||||
Net Income Margin % | -12.68 | -13.1 | -14.72 | -20.05 | -23.38 | |||||
Net Avail. For Common Margin % | -12.68 | -13.1 | -14.72 | -20.05 | -23.38 | |||||
Normalized Net Income Margin | -9.79 | -11.6 | -9.06 | -12.48 | -15.13 | |||||
Levered Free Cash Flow Margin | -6.72 | -4.69 | -7.81 | 1.86 | -16.92 | |||||
Unlevered Free Cash Flow Margin | -5.89 | -4.03 | -6.86 | 4.04 | -14.18 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.52 | 0.65 | 0.76 | 0.7 | 0.65 | |||||
Fixed Assets Turnover | 1.61 | 1.9 | 1.96 | 1.96 | 1.81 | |||||
Receivables Turnover (Average Receivables) | 6.09 | 6.82 | 6.43 | 6.44 | 6.18 | |||||
Inventory Turnover (Average Inventory) | 2.49 | 2.72 | 2.66 | 2.6 | 2.41 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 3.45 | 1.42 | 1.46 | 1.83 | 1.42 | |||||
Quick Ratio | 2.77 | 0.93 | 0.86 | 1.41 | 0.86 | |||||
Operating Cash Flow to Current Liabilities | -0.34 | -0.07 | -0.24 | -0.14 | -0.52 | |||||
Days Sales Outstanding (Average Receivables) | 59.97 | 53.55 | 56.73 | 56.85 | 59.07 | |||||
Days Outstanding Inventory (Average Inventory) | 146.59 | 134.15 | 137.33 | 140.72 | 151.46 | |||||
Average Days Payable Outstanding | 73.21 | 76.25 | 87.17 | 83.52 | 84.1 | |||||
Cash Conversion Cycle (Average Days) | 133.34 | 111.44 | 106.89 | 114.05 | 126.43 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 27.2 | 31.36 | 93.42 | 189.39 | 1.13K | |||||
Total Debt / Total Capital | 21.38 | 23.87 | 48.3 | 65.44 | 91.85 | |||||
LT Debt/Equity | 21.66 | 23.46 | 77.35 | 124.74 | 695.54 | |||||
Long-Term Debt / Total Capital | 17.03 | 17.86 | 39.99 | 43.11 | 56.7 | |||||
Total Liabilities / Total Assets | 46.19 | 56.09 | 67.56 | 84.35 | 97.23 | |||||
EBIT / Interest Expense | -14.18 | -12.06 | -6.48 | -4.65 | -3.52 | |||||
EBITDA / Interest Expense | -6.48 | -3.86 | -1.06 | -2.16 | -1.19 | |||||
(EBITDA - Capex) / Interest Expense | -8.88 | -14.82 | -4.11 | -2.96 | -1.89 | |||||
Total Debt / EBITDA | -3.37 | -5.26 | -23.68 | -6.28 | -7.88 | |||||
Net Debt / EBITDA | 3.92 | -1.08 | -17.72 | 0.22 | -5.48 | |||||
Total Debt / (EBITDA - Capex) | -2.46 | -1.37 | -6.1 | -4.58 | -4.98 | |||||
Net Debt / (EBITDA - Capex) | 2.86 | -0.28 | -4.56 | 0.16 | -3.46 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 0.4 | 28.23 | 11.79 | -1.29 | -9.52 | |||||
Gross Profit, 1 Yr. Growth % | 0.99 | 26.54 | 10.19 | 0.46 | -8.07 | |||||
EBITDA, 1 Yr. Growth % | 10.69 | -20.15 | -27.09 | 140.01 | -24 | |||||
EBITA, 1 Yr. Growth % | 16.85 | -14.54 | -18.7 | 90.96 | -15.36 | |||||
EBIT, 1 Yr. Growth % | 9.02 | -13.62 | -12.85 | 62.06 | -13.95 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -48.1 | 35.49 | 27.96 | 36.8 | 6.6 | |||||
Net Income, 1 Yr. Growth % | -48.66 | 32.54 | 25.63 | 34.4 | 5.53 | |||||
Normalized Net Income, 1 Yr. Growth % | -39.34 | 51.86 | -12.68 | 36.03 | 9.63 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -51.92 | 20.65 | 25.98 | 34.21 | 5.88 | |||||
Accounts Receivable, 1 Yr. Growth % | 9.02 | 19.55 | 17.5 | -17.41 | 8.44 | |||||
Inventory, 1 Yr. Growth % | 0.73 | 37.72 | 0.98 | -3.44 | -5.14 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -0.73 | 18.3 | -0.06 | -3.01 | -1.1 | |||||
Total Assets, 1 Yr. Growth % | 7.74 | 0.33 | -9.05 | 25.09 | -25.24 | |||||
Tangible Book Value, 1 Yr. Growth % | 236.07 | -49.02 | -49.08 | -123.92 | 579.27 | |||||
Common Equity, 1 Yr. Growth % | 86.59 | -23.58 | -26.54 | -42.05 | -85.42 | |||||
Cash From Operations, 1 Yr. Growth % | -18.06 | -61.98 | 184.04 | -15.05 | 157.69 | |||||
Capital Expenditures, 1 Yr. Growth % | -55.64 | 363.63 | -54.84 | -40.74 | -1.29 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -37.1 | -10.54 | 86.29 | -123.45 | -926.62 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -38.72 | -12.24 | 90.22 | -158.13 | -417.85 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | -1.03 | 13.47 | 19.73 | 5.05 | -5.49 | |||||
Gross Profit, 2 Yr. CAGR % | -0.72 | 13.04 | 18.08 | 5.21 | -3.89 | |||||
EBITDA, 2 Yr. CAGR % | 13.94 | -5.98 | -23.7 | 32.28 | 35.04 | |||||
EBITA, 2 Yr. CAGR % | 11.53 | -0.07 | -16.65 | 24.6 | 27.13 | |||||
EBIT, 2 Yr. CAGR % | 10.21 | -2.96 | -13.23 | 18.84 | 18.09 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -35.12 | -16.14 | 31.67 | 32.31 | 20.76 | |||||
Net Income, 2 Yr. CAGR % | -33.07 | -17.51 | 29.04 | 29.94 | 19.09 | |||||
Normalized Net Income, 2 Yr. CAGR % | -23.31 | -4.02 | 15.16 | 8.99 | 22.12 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -36.23 | -23.84 | 23.29 | 30.03 | 19.21 | |||||
Accounts Receivable, 2 Yr. CAGR % | 2.58 | 14.16 | 18.52 | -1.49 | -5.37 | |||||
Inventory, 2 Yr. CAGR % | -6.55 | 17.78 | 17.93 | -1.26 | -4.29 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 19.03 | 8.37 | 8.74 | -1.55 | -2.06 | |||||
Total Assets, 2 Yr. CAGR % | 8.43 | 3.97 | -4.47 | 6.67 | -3.3 | |||||
Tangible Book Value, 2 Yr. CAGR % | 626.83 | 30.89 | -49.05 | -65.1 | 27.46 | |||||
Common Equity, 2 Yr. CAGR % | 59.13 | 19.41 | -25.08 | -34.75 | -70.93 | |||||
Cash From Operations, 2 Yr. CAGR % | 7.5 | -44.19 | 3.92 | 55.33 | 47.95 | |||||
Capital Expenditures, 2 Yr. CAGR % | -56.52 | 43.41 | 44.69 | -48.27 | -23.52 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -24.1 | -24.99 | 29.1 | -33.9 | 39.07 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -26.32 | -26.67 | 29.21 | 5.16 | 35.86 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 10.52 | 7.89 | 12.91 | 12.27 | -0.05 | |||||
Gross Profit, 3 Yr. CAGR % | 13.29 | 7.64 | 12.08 | 11.89 | 0.59 | |||||
EBITDA, 3 Yr. CAGR % | -12.01 | 1.21 | -13.62 | 11.8 | 9.96 | |||||
EBITA, 3 Yr. CAGR % | -7.44 | 2.06 | -6.71 | 9.88 | 9.53 | |||||
EBIT, 3 Yr. CAGR % | -5.83 | 1.61 | -6.37 | 6.86 | 6.72 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | -16.85 | -17.07 | -3.46 | 33.36 | 23.12 | |||||
Net Income, 3 Yr. CAGR % | -14.36 | -15.95 | -5.09 | 30.8 | 21.23 | |||||
Normalized Net Income, 3 Yr. CAGR % | -4.78 | -3.69 | -7 | 21.73 | 9.2 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -17.17 | -21.13 | -9.93 | 26.83 | 21.42 | |||||
Accounts Receivable, 3 Yr. CAGR % | 1.38 | 7.95 | 15.26 | 5.07 | 1.71 | |||||
Inventory, 3 Yr. CAGR % | -4.43 | 6.35 | 11.89 | 10.33 | -2.57 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 26.35 | 18.79 | 5.48 | 4.67 | -1.4 | |||||
Total Assets, 3 Yr. CAGR % | 1.44 | 5.66 | -0.56 | 4.51 | -5.25 | |||||
Tangible Book Value, 3 Yr. CAGR % | 78.33 | 199.75 | -4.44 | -60.4 | -6.12 | |||||
Common Equity, 3 Yr. CAGR % | 18.13 | 24.61 | 1.56 | -31.22 | -60.4 | |||||
Cash From Operations, 3 Yr. CAGR % | -10.33 | -23.98 | -4 | -2.84 | 83.88 | |||||
Capital Expenditures, 3 Yr. CAGR % | -0.45 | -4.29 | -2.43 | 7.45 | -35.84 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 5.65 | -19.83 | 1.58 | -26.88 | 53.31 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 4.62 | -21.9 | 0.76 | -0.99 | 51.99 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 9.39 | 13.75 | 14.12 | 6.74 | 5.15 | |||||
Gross Profit, 5 Yr. CAGR % | 10.43 | 13.41 | 15.18 | 6.66 | 5.4 | |||||
EBITDA, 5 Yr. CAGR % | -19.82 | -15.73 | -16.88 | 12.65 | 3.28 | |||||
EBITA, 5 Yr. CAGR % | -15.43 | -10.69 | -11.24 | 10.54 | 5.58 | |||||
EBIT, 5 Yr. CAGR % | -11.77 | -7.13 | -8.86 | 8.18 | 2.74 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | -20.72 | -8.1 | -0.06 | -0.03 | 5.59 | |||||
Net Income, 5 Yr. CAGR % | -19.48 | -7.26 | 0.9 | 0.05 | 3.93 | |||||
Normalized Net Income, 5 Yr. CAGR % | -14.51 | 0.24 | 2.74 | 1.19 | 3.71 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | -23.77 | -12.34 | -2.89 | -3.67 | 0.76 | |||||
Accounts Receivable, 5 Yr. CAGR % | 3.42 | 4.42 | 7.92 | 4.07 | 6.52 | |||||
Inventory, 5 Yr. CAGR % | -0.32 | 5.93 | 3.95 | 3.24 | 5.11 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 27.91 | 30.51 | 18.99 | 10.19 | 2.4 | |||||
Total Assets, 5 Yr. CAGR % | 10.35 | 2.63 | -0.97 | 6.06 | -1.67 | |||||
Tangible Book Value, 5 Yr. CAGR % | 5.93 | -20.32 | 8.04 | 26.82 | 7.23 | |||||
Common Equity, 5 Yr. CAGR % | 7.77 | -8.88 | -1.54 | -3.8 | -38.42 | |||||
Cash From Operations, 5 Yr. CAGR % | -14.77 | -23.74 | -4.88 | 1.17 | 14.14 | |||||
Capital Expenditures, 5 Yr. CAGR % | 7.07 | 40.01 | 15.61 | -25.17 | -11.49 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 3.62 | -16.88 | 14.47 | -25.78 | 15.18 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 3.01 | -18.87 | 13.84 | -12.03 | 13.56 |
- Stock Market
- Equities
- BNN Stock
- Financials BRAIN Biotech AG
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















